Hepatitis SA's Singing O'livers send greetings in 40 degree heat...
The Pharmaceutical Benefits Advisory Committee (PBAC) has given positive recommendations for PBS listing for more hepatitis C direct-acting antiviral drugs.
The national organisation representing people who use drugs, AIVL, has applauded the Australian Greens' courageous leadership in adopting an evidence based drug policy that focuses on saving lives.
Misinformation and hysteria over saliva have resurfaced again as South Australians waded into the Du Plessiss ball tampering debate.
The Federal Government’s response to the 'Silent Disease' inquiry into hepatitis C in Australia falls well short of what anyone living with hepatitis C could have hoped.
A unique longitudinal real life study on entecavir-treated children and adolescents have found that HBV DNA results at six and twelve months after starting treatment, are predictors of viral suppression.
The Australasian Hepatology Association has released guidelines for health professionals on helping people adhere to their hepatitis C treatment.
A clinical trial is now open for people who have been diagnosed with chronic Hepatitis B Virus (HBV) infection, who have not had treatment for this condition in the last 2 years. Other entry requirements apply.
